Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials.

Munveer ThindHarry J CrijnsGerald V NaccarelliJames A ReiffelValérie Corp Dit GentiMattias WielochAndrew KorenPeter R Kowey

Published in: Journal of cardiovascular electrophysiology (2020)

Patients requiring baseline cardioversion represent a distinct population, having more underlying cardiovascular disease and experiencing a shorter time to AF/AFL recurrences. Dronedarone was associated with improved efficacy vs placebo regardless of cardioversion status.

Keyphrases

atrial fibrillation
cardiovascular disease
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
catheter ablation
clinical trial
metabolic syndrome
patient reported outcomes
double blind
combination therapy